Skip to content
Menu

Jupiter Neurosciences, Inc. JUNS

Full chart Compare
Set alert

Price alert · JUNS

All alert types
1.52 USD 0.00 (+0.00%)

As ofNov 19, 2026, 3:46 PM EST

1.51 Day range 1.64
1.37 52-week range 101.25
YTD
-98.01%
1 year
-98.44%

5D -0.68 (-30.91%)

1.502WedThuFriMonTue1.52
Market cap
2.00M
EPS (ttm)
-22.53
Shares out
32.88M
YTD return
-98.01%
1-year return
-98.44%
50-day average
9.68
200-day average
9.68
Enterprise value
295.46M
Volume
7.64K
Avg volume
888.82K
Open
1.64
Previous close
1.52
Day's range
1.51 – 1.64
52-week range
1.37 – 101.25
Analysts
Strong Buy
Price target
30.00 (+1873.7%)

Key statistics

Total cash
14.85K
Total debt
2.34M

Fundamental scorecard

1 of 25 checks passed on JUNS’s reported financials

ValueGrowthProfitabilityHealthDividend

1of 25 checks passed

  • Value 0 of 5
  • Growth 0 of 5
  • Profitability 0 of 5
  • Financial health 1 of 5
  • Dividend 0 of 5

Statements to Sep 30, 2026.

Financials — quick view

All financials
JUNS Revenue — quarterly 13.94K
JUNS Net income — quarterly -7.22M
JUNS EPS — quarterly -7.42

About Jupiter Neurosciences, Inc.

Jupiter Neurosciences, Inc., a clinical stage research and development pharmaceutical company, develops resveratrol platform products primarily for the treatment of neuroinflammation. It is developing JNS101, which is in Phase II trial for the treatment of Friedreich's Ataxia, a rare inherited disease that causes damage to the nervous system, as well as mobility dysfunctions; and JNS108 that is in Phase II trial for treating mild cognitive impairment/early Alzheimer's disease. The company is also developing JNS102, which is in Phase II trial for the treatment of mucopolysaccharidosis type 1; and JNS107 that is in Phase II trial for treating mitochondrial encephalopathy, lactic acidosis, and stroke-like episodes syndrome. In addition, it is developing JNS115, which is in Phase II trial for the treatment of Parkinson's disease. The company was formerly known as Jupiter Orphan Therapeutics, Inc. and changed its name to Jupiter Neurosciences, Inc. in August 2021. Jupiter Neurosciences, Inc. was incorporated in 2015 and is headquartered in Jupiter, Florida.

Sector
Healthcare
Industry
Biotechnology
Country
United States

News

No recent headlines

Headlines appear here as they are published.

Your note

Sign in to keep a note on JUNS — it syncs with the Stock Master app.